|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mechanically reprogrammable Pancharatnam-Berry metasurface for microwaves显示文摘Metasurfaces have enabled the realization of several optical functionalities over an ultrathin platform,fostering the exciting field of flat optics.Traditional metasurfaces are achieved by arranging a layout of static meta-atoms to imprint a desired operation on the impinging wavefront,but their functionality cannot be altered.Reconfigurability and programmability of metasurfaces are the next important step to broaden their impact,adding customized on-demand functionality in which each meta-atom can be individually reprogrammed.We demonstrate a mechanical metasurface platform with controllable rotation at the meta-atom level,which can implement continuous Pancharatnam–Berry phase control of circularly polarized microwaves.As the proof-of-concept experiments,we demonstrate metalensing,focused vortex beam generation,and holographic imaging in the same metasurface template,exhibiting versatility and superior performance.Such dynamic control of electromagnetic waves using a single,low-cost metasurface paves an avenue towards practical applications,driving the field of reprogrammable intelligent metasurfaces for a variety of applications. | Quan Xu Xiaoqiang Su Xueqian Zhang Lijuan Dong Lifeng Liu Yunlong Shi Qiu Wang Ming Kang Andrea Alù Shuang Zhang Jiaguang Han Weili Zhang | 2022 | Advanced Photonics2022，4，1： | 5 |
| 2 | Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV:a phase 2 trial显示文摘The increased coronavirus disease 2019(COVID-19)breakthrough cases pose the need of booster vaccination.We conducted a randomised,double-blinded,controlled,phase 2 trial to assess the immunogenicity and safety of the heterologous prime-boost vaccination with an inactivated COVID-19 vaccine(BBIBP-CorV)followed by a recombinant protein-based vaccine(NVSI-06-07),using homologous boost with BBIBP-CorV as control.Three groups of healthy adults(600 individuals per group)who had completed two-dose BBIBP-CorV vaccinations 1–3 months,4–6 months and≥6 months earlier,respectively,were randomly assigned in a 1:1 ratio to receive either NVSI-06-07 or BBIBP-CorV boost.Immunogenicity assays showed that in NVSI-06-07 groups,neutralizing antibody geometric mean titers(GMTs)against the prototype SARS-CoV-2 increased by 21.01–63.85 folds on day 28 after vaccination,whereas only 4.20–16.78 folds of increases were observed in control groups.For Omicron variant,the neutralizing antibody GMT elicited by homologous boost was 37.91 on day 14,however,a significantly higher neutralizing GMT of 292.53 was induced by heterologous booster.Similar results were obtained for other SARS-CoV-2 variants of concerns(VOCs),including Alpha,Beta and Delta.Both heterologous and homologous boosters have a good safety profile.Local and systemic adverse reactions were absent,mild or moderate in most participants,and the overall safety was quite similar between two booster schemes.Our findings indicated that NVSI-06-07 is safe and immunogenic as a heterologous booster in BBIBP-CorV recipients and was immunogenically superior to the homologous booster against not only SARS-CoV-2 prototype strain but also VOCs,including Omicron. | Nawal Al Kaabi Yun Kai Yang Jing Zhang Ke Xu Yu Liang Yun Kang Ji Guo Su Tian Yang Salah Hussein Mohamed Saif ElDein Shuai Shao Sen Sen Yang Wenwen Lei Xue Jun Gao Zhiwei Jiang Hui Wang Meng Li Hanadi Mekki Mekki Walid Zaher Sally Mahmoud Xue Zhang Chang Qu Dan Ying Liu Jing Zhang Mengjie Yang Islam Eltantawy Peng Xiao Zhao Nian Wang Jin Liang Yin Xiao Yan Mao Jin Zhang Ning Liu Fu Jie Shen Liang Qu Yun Tao Zhang Xiao Ming Yang Guizhen Wu Qi Ming Li | 2022 | Signal Transduction and Targeted Therapy2022，7，7： | 2 |
| 3 | Development of a multivalent inac-tivated vaccine against pathogenic Escherichia coli infection in forestmusk deer显示文摘 | LUO Y KANG J P CHENG J Ge t al | 2010 | Agricultural Science&Technology2010，11，910： | 1 |
| 4 | Efficacy and safety of sorafenib in patients in the Asia - Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double - blind, placebo con- trolled trial 显示文摘 | Cheng AL Kang YK Chen Z | 2009 | Lancet Onco12009，10，： | 1 |
| 5 | Phenylbutyric acid protects against spatial memory deficits in a model of repeated electroconvulsive therapy显示文摘 | Yao ZH Kang X Yang L ct al | 2014 | Curr Neurovasc Res2014，11，2： | 1 |
| 6 | Efficacy and safety of sorafenib in patients in the Asia - Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double- blind, placeboeontrolled trial 显示文摘 | Cheng AL Kang YK Chen Z | 2009 | Lancet Oncol2009，10，： | 1 |
| 7 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomized double-blind, placebo-controlled trial显示文摘 | Cheng AL Kang YK Chert Z | 2009 | Lancet Oncol2009，10，： | 1 |
| 8 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatoeellular carcinoma: a phase IlI ran- domised, double-blind, placebo-controlled trial显示文摘 | Cheng AL Kang YK Chen Z | 2009 | Lancet 0ncol2009，10，1： | 1 |
| 9 | Clinical investigation of acupuncture in the treatment of gastric dysmotility显示文摘 | Zhang AL Chen RX Kang MF | 1994 | Chin Acupunct1994，14，1： | 1 |
| 10 | Improved glyeemic control with- out hypoglycemia in elderly diabelie patients using the ubiq- uitous healthware service,a new medical information system 显示文摘 | Lira S Kang SM Shin H el al | 2011 | Diabetes Care2011，24，9： | 1 |
| 11 | Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction:the MAGIC Cell-3-DES randomized,controlled trial显示文摘 | LEE HY NA SH et al | 2006 | Circulation2006，114，1： | 1 |
| 12 | 12-year experience of spontane- ous hemopneumothorax显示文摘 | Kim ES Kang JY Pyo CH et al | 2008 | Ann Thorac Cardiovasc Surg2008，14，3： | 1 |
| 13 | Optimized solid-state synthesisof LiFcP04 cathode materials using ball-milling显示文摘 | KANG H C JUN D K JIN B ct al | 2008 | Journal of Pow-er Sources2008，179，1： | 1 |
| 14 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial 显示文摘 | Cheng AL Kang YK Chen Z | 2009 | Lancet Oncol2009，10，1： | 1 |
| 15 | An Experimental Study on Oil Discharge Ratio at Inverter-Driven High Shell Pressure Scroll Compressor Us- ing R410A/PVE 显示文摘 | 5] YOON Pihyun KANG Donghoon KIM Cholhwan et al | 2011 | International Journal of Refrigera- tion2011，34，1： | 1 |
| 16 | Efficacy and safety of sor- afenib in patients in the Asia-Pacific region with advanced hepa- tocellular carcinoma: A phase B显示文摘 | Cheng AL Kang YK Chen Z | 2009 | Lancet 0ncol2009，10，1： | 1 |
| 17 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial显示文摘 | Cheng AL Kang YK Chen Z | 2009 | Lancet Oncol2009，10，1： | 1 |
| 18 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:aphase III randomised,double-blind,placebo-controlled trial显示文摘 | Cheng AL Kang YK Chen Z | 2009 | Lancet Oncol2009，10，1： | 1 |
| 19 | Efficacy and safety of sorafenib inpatients in the Asia-Pacific region with ad- vanced hepatocellular carcinoma:a phase In randomised, double-blind,placebo-controlled trial 显示文摘 | Cheng AL Kang YK Chen Z | 2009 | Lancet Oncol2009，10，1： | 1 |
| 20 | Efficacy and safety of sorafenib in patients in the Asia-Pacifie region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, piacebo-controlled triat 显示文摘 | CHENG AL KANG YK CHEN Z | 2009 | Lancet2009，10，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员